Brokerages Anticipate Selecta Biosciences Inc. (SELB) to Announce ($0.48) Earnings Per Share
Selecta Biosciences Inc. (NASDAQ:SELB) has received a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company.
Brokers have set a 12 month consensus price objective of $23.67 for the company and are anticipating that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also given Selecta Biosciences an industry rank of 109 out of 265 based on the ratings given to related companies.
SELB has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Selecta Biosciences from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Tuesday, September 20th. Needham & Company LLC initiated coverage on Selecta Biosciences in a report on Monday, July 18th. They issued a “buy” rating and a $28.00 target price for the company. Stifel Nicolaus initiated coverage on Selecta Biosciences in a report on Monday, July 18th. They issued a “buy” rating and a $23.00 target price for the company. Finally, Canaccord Genuity initiated coverage on Selecta Biosciences in a report on Monday, July 18th. They issued a “buy” rating and a $20.00 target price for the company.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/brokerages-anticipate-selecta-biosciences-inc-selb-to-announce-0-48-earnings-per-share.html
Selecta Biosciences (NASDAQ:SELB) traded up 0.13% during trading on Wednesday, reaching $16.02. 3,422 shares of the company’s stock were exchanged. Selecta Biosciences has a 12 month low of $10.26 and a 12 month high of $18.88. The firm has a 50 day moving average of $13.79 and a 200-day moving average of $13.28.
Several large investors have recently modified their holdings of SELB. Marshall Wace LLP bought a new position in Selecta Biosciences during the second quarter valued at approximately $506,000. Laurion Capital Management LP bought a new position in Selecta Biosciences during the second quarter valued at approximately $350,000. Perceptive Advisors LLC bought a new position in Selecta Biosciences during the second quarter valued at approximately $6,296,000. FMR LLC bought a new position in Selecta Biosciences during the second quarter valued at approximately $3,997,000. Finally, Vanguard Group Inc. bought a new position in Selecta Biosciences during the second quarter valued at approximately $1,679,000. Institutional investors and hedge funds own 41.02% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.